Shinobi Therapeutics Inc.
Founded 2023 · 38 employees on LinkedIn · 5 known investors
Shinobi develops next-generation cell therapies using iPSC (induced pluripotent stem cell) research, genetic engineering, and clinical infrastructure. The company operates across Japan and the U.S., combining biotechnology and genetic engineering capabilities in cell therapy development.
Investors · 5
Competitors · 2
by search overlapBioworld14 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Northwest Biotherapeutics13 shared keywordsNorthwest Biotherapeutics is a clinical-stage biotechnology company developing personalized cancer vaccines, marketed under the DCVax platform, that use activated dendritic cells to treat a range of solid tumor cancers. Its product lines include DCVax-L, DCVax-Direct, and DCVax-Prostate.
Companies competing with Shinobi Therapeutics Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Shinobi Therapeutics Inc. do?
- Shinobi develops next-generation cell therapies using iPSC (induced pluripotent stem cell) research, genetic engineering, and clinical infrastructure. The company operates across Japan and the U.S., combining biotechnology and genetic engineering capabilities in cell therapy development.
- Who are Shinobi Therapeutics Inc.'s investors?
- Shinobi Therapeutics Inc.'s investors include Astellas Venture Management LLC, F-Prime Capital, Fast Track Initiative, JIC Venture Growth Investments, Kyoto University Innovation Capital.